- About NephU
- Meet The Team
- Supporting Organizations
- Community Advisors
- Contact Us
- Diversity, Equity, & Inclusion
- Resource Center
- Rare Kidney Diseases (PKD, IgAN, & Others)
- Kidney Disease & Mental Health
- Kidney Disease & Comorbid Conditions
- Transplantation & Dialysis
- NephU Nutrition & The NephChefTM
- Patient Resources
Implementation of the End-Stage Renal Disease Treatment Choices (ETC) Model began on January 1, 2021. In this informative webinar, Mark Neumann and Amy Kozsuch discuss the details of this payment model and how it impacts providers across the End-Stage Renal Disease care spectrum.
*Amy Kozsuch and Mark Neumann are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Aaron Emmel is an employee of OPDC.
Health Map Solutions*
Amy Kozsuch is the Vice President of Clinical Products at Healthmap. In this role she is responsible for expanding and developing innovative programs that advance early detection of chronic kidney disease, defer its progression, and deliver improved patient outcomes at lower costs. Amy has 30 years of experience in the kidney health industry, having worked as a nurse administrator, director of clinical operations and corporate development in the past. She serves on several health industry board of directors, most recently as executive board president for the National Kidney Foundation of Florida. Amy earned her MSN, MBA, and Health Care Administration degrees from University of Phoenix, where she is currently a doctoral candidate.
Healthcare Writer & Editor*
Mark Neumann started his career as a healthcare writer and editor in 1984 and has been covering clinical, regulatory, and economic issues in the kidney care field for the past 30 years. He is a previous winner of the President’s Award from the National Association of Nephrology Technicians and Technologists and a Medal of Excellence Award winner from the American Association of Kidney Patients.
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Aaron Emmel, PharmD, MHA, BCPS, joined Otsuka in 2018 and is currently a Senior Medical Science Liaison on our Nephrology South Team. Dr Emmel earned his Doctor in Pharmacy from the University of Florida in 2007 and his Masters in Health Administration from the University of North Florida in 2015. He has 10 years of experience as a clinical pharmacist, helping to develop and implement numerous clinical programs focused on ICU care, nutrition support, and antimicrobial stewardship. Additionally, he served as an administrator for a multi-specialty Clinically Integrated Network and ACO, helping to develop a Population Health Management strategy that included a coordinated approach to managing Chronic Kidney Disease. He has served as an Associate Clinical Professor for the University of Florida College of Pharmacy, delivering lectures and precepting students on Advanced Pharmacy Practice Experience rotations. Dr Emmel is Board Certified as a Pharmacotherapy Specialist by the Board of Pharmacy Specialties.
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.May 2020 MRC2.CORP.X.04767
February 14 from 12:00 pm to 1:00 pm
- Resource Center
- Patient Resources